StockNews.com Begins Coverage on NeuroMetrix (NASDAQ:NURO)

StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note released on Friday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NURO stock opened at $3.35 on Friday. The stock’s 50 day moving average price is $3.57 and its 200 day moving average price is $3.76. The firm has a market cap of $6.74 million, a P/E ratio of -0.53 and a beta of 2.30. NeuroMetrix has a 1 year low of $2.66 and a 1 year high of $6.64.

Institutional Investors Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Cerity Partners LLC bought a new stake in NeuroMetrix, Inc. (NASDAQ:NURO) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned about 2.80% of NeuroMetrix at the end of the most recent quarter. Institutional investors own 19.40% of the company’s stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.